
CORRECTION



Tania A. Smith^{1*}, Carlos Hoyo-Vadillo¹, Akosua Agyeman Adom², Liliana Favari-Perozzi¹, Silke Gastine², Hakim-Moulay Dehbi³, Beatriz Villegas-Lara⁴, Eduardo Mateos⁴, Yessica Sara Pérez González⁴, Maria D. Navarro-Gualito⁴, Alejandra S. Cruz-Carbajal⁴, Miguel A. Cortes-Vazquez⁴, Carolina Bekker-Méndez⁴, Charmina Aguirre-Alvarado⁴, Gisela Aguirre-Gil⁵, Lucero Delgado-Pastelin⁵, Andrew Owen⁶, David Lowe⁷, Joseph Standing² and Jorge Escobedo⁴

Correction: Trials 23, 583 (2022) https://doi.org/10.1186/s13063-022-06533-0

The original publication of this article [1] erroneously contained "2X2 design" in the title whilst the study itself did not include a 2×2 design. The original article has been updated.

Reference

 Smith T, et al. Favipiravir and/or nitazoxanide: a randomized, doubleblind, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FAN-TAZE). Trials. 2022;23:583. https://doi.org/10.1186/s13063-022-06533-0.

Published online: 22 May 2023

The original article can be found online at https://doi.org/10.1186/s13063-022-06533-0.

*Correspondence:

Tania A. Smith

tania.smith@cinvestav.mx

- ¹ CINVESTAV-IPN, Mexico, Mexico
- ² ICH-UCL, London, UK
- ³ Clinical Trials Unit, UCL, London, UK
- ⁴ IMSS, Mexico, Mexico
- ⁵ Hakken Enterprise, Cuernavaca, Mexico
- ⁶ University of Liverpool, Liverpool, UK

⁷ Division of Infection and Immunity, UCL, London, UK



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedicated in a credit line to the data.